<DOC>
	<DOCNO>NCT00749099</DOCNO>
	<brief_summary>The overall purpose research demonstrate ( measure ) intestinal availability lipase , amylase , protease ( enzymes body shortage ) PANCRECARB® administer meal .</brief_summary>
	<brief_title>Bioavailability Pancreatic Enzymes Human Upper Intestine ( Duodenum Jejunum )</brief_title>
	<detailed_description>Eligible patient placebo-controlled study confirm exocrine pancreatic insufficiency stool pancreatic elastase &lt; 75 mcg/g . Patients satisfied inclusion criterion prepare endoscopic placement three Liguory nasal biliary aspiration catheter : one 8.5 fr . catheter distal duodenum aspiration , one 7.0 fr . catheter first portion duodenum infusion PEG marker ( 4 mL/min ) one 7.0 fr . stomach aspiration . Baseline sample obtain gastric distal duodenal port place ice . Subjects ask swallow 5 capsule placebo ( Phase I ) test drug ( PANCRECARB® ( pancrelipase ) - Phase II ) standardize Lundh meal . Gastric sample collect hour duodenal sample collect every 15 minute phase ( 4 hour ) . All collect sample test follow parameter demonstrate bioavailability enzyme originate PANCRECARB® ( pancrelipase ) : lipase , amylase protease activity , pH ( bicarbonate ) , protein fingerprint SDS-PAGE analysis .</detailed_description>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Documented chronic pancreatitis , alcohol induce chronic pancreatitis cystic fibrosis Documented pancreatic enzyme insufficiency determine spot fecal elastase1 &lt; 75 mcg/g stool time inclusion study Required daily exogenous enzyme supplementation commercially available pancreatic enzyme &gt; 18 year age Male female subject qualify Able swallow capsule Clinically stable evidence acute medical condition History steatorrhea History fibrosing colonopathy CF subject Current diagnosis history distal intestinal obstruction syndrome ( DIOS ) past 4 month Known contraindication , sensitivity hypersensitivity porcine pancreatic enzyme Active liver disease ALT AST &gt; 3 time upper limit normal Bilirubin &gt; 3 time upper limit normal Acute pancreatitis acute exacerbation chronic pancreatitis Acute treatment systemic ( oral IV ) antibiotic two week prior screen Subjects erythromycin unwilling discontinue treatment two week prior screen Receiving treatment antacid H2 receptor blocker proton pump inhibitor unable discontinue treatment prior day 1 Inability cooperate noncompliant require study procedure Pregnant , breast feeding Current daily prescribed schedule use narcotic ( patient require PRN use narcotic exclude ) Poorly control diabetes A medical condition investigator deem significant enough interfere ability subject participate intubation study interfere assessment enzyme bioavailability Stomach pH &gt; 4 Small bowel disease ( i.e . celiac disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>